Podcasts about chemaly

10th October is World Mental Health Day

What comes to your mind when you picture someone who's resilient?  Usually, we hear that it's one person who's faced a setback, and they remain hopeful and willing to work through the challenges to return to some sort of life they had before. Maybe you've heard the phrase “pick themselves up by their bootstraps” to describe this type of person. We know we have. But that doesn't always work, as we continually say.  We have a guest today who's going to help us critically examine that image we have - and help us understand what we're missing.  She'll tell us we need to think critically about when it comes to glorifying resilience, especially if we're doing it for individual gain or to showcase individual strength, without realizing that the opposite of resilience is loneliness – we have to remember the communal and community contribution to the ability to be resilient. We're at a time in history where it feels - no matter your perspective - like the world is burning down around us. We want to trust that we will still be standing. To do it, we need to know when to be optimistic and when to be strategically pessimistic, not beat ourselves up when we're coming up against moral injury, embrace certain ways of thinking - cognitive flexibility, for those who want the big words - and hold onto hope for the collective, above all.   What to listen for: The inaccurate understanding Americans have of resilience – and how it needs to shift from an individual to a collective focus: the opposite of resilience is loneliness.  The mind-blowing study that shows us social status matter – and reexamining preconceptions and research in positive psychology, male-focused hardiness, and more. Rethinking popular portrayals of the upcoming generation – that, maybe, “younger people aren't distressed because they lack the right mindset or don't understand what is happening around them. They are distressed because the world is distressing, and adults have failed them.”  How do we find hope when it feels like the world is burning around us? Have openness to difference, openness to change, and acceptance of limits.  About Soraya:  Soraya Chemaly is an award-winning author and activist. As a cultural critic, she writes and speaks frequently about gender norms, social justice, free speech, sexualized violence, politics, and technology. The former Executive Director of The Representation Project and Director and co-founder of the Women's Media Center Speech Project, she has long been committed to expanding women's civic and political participation. Soraya is also the author of The Resilience Myth: New Thinking on Grit, Strength, and Growth after Trauma, a thought-provoking exploration that challenges our most dearly held, common myths of resilience and urges us to shift our perspective from prioritizing individualized traits and skills to uplifting collective care and open-ended connections with our communities. Her first book, Rage Becomes Her: The Power of Women's Anger, was recognized as a Best Book of 2018 by the Washington Post, Fast Company, Psychology Today, and NPR and has been translated into multiple languages. She is a contributor to several anthologies, most recently Free Speech in the Digital Age and Believe Me: How Trusting Women Can Change The World.  Soraya is also a co-producer of a WMC #NameItChangeIt PSA highlighting the effects of online harassment on women in politics in America.  Her work is featured widely in media, documentaries, books, and academic research. As an activist, Ms. Chemaly also spearheaded several successful global campaigns challenging corporations to address online hate and harassment, restrictive content moderation and censorship, and institutional biases that undermine equity and negatively affect free speech. Prior to 2010, Ms. Chemaly spent more than fifteen years as an executive and consultant in the media and data technology industries.  

In this, our last episode of Season One, the team at Dear Beth welcomes acclaimed, award-winning author and activist Soraya Chemaly. Chemaly's book, Rage Becomes Her: The Power of Women's Anger poses a simple, yet provocative question: Why do we not appreciate women's anger as a catalyst for social change? In their conversation with Chemaly, Brea and Leah unpack why her book is so influential - particularly for those working in male-dominated fields such as law. They also explore the reasons why women's anger has long been suppressed and be-littled, while the anger of men is allowed more expression and given more validity. Chemaly encourages listeners to consider how the emotion of anger can be viewed in a different light: as an emotion that can be channeled for personal growth and a powerful tool to fight against injustice.  In the last half of the episode, Brea, Beth, Leah and Jen sit down to reflect on their favorite moments from the past season and the power of storytelling which they captured in their own book: Creating a Seat at the Table: Reflections From Women in Law. Sharing their perspectives on the book and what they learned about the experience of women in law is Professor of Law Dwight Newman and Law Student Brock Melnyk both of the University of Saskatchewan Law School. And we also hear once again from entertainment lawyer and Canadian musician Safwan Javed who shares his perspective on allyship and how to use one's privilege for good.    GUEST BIO: Soraya Chemaly is an award-winning author and activist. She writes and speaks frequently on topics related to gender, inclusivity, social justice, free speech, sexualized violence, and technology. The former Executive Director of The Representation Project and Director and co-founder of the Women's Media Center Speech Project, she has long been committed to expanding women's civic and political participation. Soraya is also the author of Rage Becomes Her: The Power of Women's Anger, which was recognized as a Best Book of 2018 by the Washington Post, Fast Company, Psychology Today, and NPR and has been translated into multiple languages. She is a contributor to several anthologies, most recently Free Speech in the Digital Age and Believe Me: How Trusting Women Can Change The World.  Soraya is also a co-producer of a WMC #NameItChangeIt PSA highlighting the effects of online harassment on women in politics in America.  Her work is featured widely in media, documentaries, books, and academic research. As an activist, Ms. Chemaly has spearheaded several successful global campaigns challenging corporations to address online hate and harassment, restrictive content moderation and censorship, and institutional biases that undermine equity and negatively affect free speech. Prior to 2010, Ms. Chemaly spent more than fifteen years as a market development executive and consultant in the media and data technology industries. Her upcoming book, The Resilience Myth: New Thinking on Strength, Grit, and Growth After Trauma, will be released May 2024. Photo Credit: Elizabeth Dranitzke Additional Reading:  CHEMALY, S. (2024). Rage becomes her. SIMON & SCHUSTER LTD.  Chemaly, S. (May 2024). Resilience myth: New thinking on grit, strength, and growth after trauma. Atria Books.  Bilson, B., Howie, L., & Lowenberger, B. (2023). Creating a seat at The table: Reflections From Women in Law. University of Regina Press.  Co-Editor Bios:  Beth Bilson, KC, PhD has enjoyed a career of teaching, writing, deaning, arbitrating, and community engagement that began at the University of Saskatchewan in 1979, and she has never run out of interesting things to do. Leah Howie, BEng, BSc, LLB, LLM lives in beautiful Saskatoon with her husband, two daughters, two dogs, and two cats. She loves reading, connecting people, travelling, and spending time outside on the prairies, in the mountains, by the river, and in the boreal forest. She enjoys thinking about ways to improve the law in her work in the area of law reform, and teaching and coaching law students as a sessional lecturer for the College of Law. Brea Lowenberger, BA, JD, LLM is a lifelong learner and collaborator who hopes to leave the individuals and communities she interacts with a bit better than she found them. She is passionate about teaching and implementing design strategies that improve access to justice for Saskatchewan residents through her roles as Access to Justice coordinator, director of CREATE Justice, and sessional lecturer for the College of Law. When she isn't working, she enjoys adventures with family and friends, travelling, being active, nature, reading, and creating music and art.  

It's time for episode 367 of the Mobile Tech Podcast with guests Ephrem Chemaly (MediaTek) and Ray Wong (Inverse) -- brought to you by MediaTek. This episode comes in two parts. First, we explore how MediaTek's Dimensity Auto platform is helping car manufacturers make better software defined vehicles (SDVs). Second (20:17), we discuss standalone AI devices, review the OnePlus Watch 2, and cover the latest news including Nothing's Phone (2a) Community Creation Project, Qualcomm's Snapdragon 8s Gen 3, and more.Episode Links- Support the podcast on Patreon: https://www.patreon.com/tnkgrl- Donate: https://tnkgrl.com/tnkgrl/- MediaTek: http://www.poweredbymediatek.com/ (sponsor)- MediaTek Dimensity Auto: https://www.mediatek.com/products/automotive- Ephrem Chemaly: https://www.linkedin.com/in/chemaly/- Ray Wong: https://twitter.com/raywongy- Your OnePlus Watch 2 review: https://www.inverse.com/tech/oneplus-watch-2-review-comparison-galaxy-watch-6-pixel-watch-2- Nothing Phone (2a) Community Creation Project: https://www.gsmarena.com/nothing_invites_its_community_to_design_package_and_customize_a_special_edition_phone_2a-news-62089.php- Qualcomm Snapdragon 8s Gen 3: https://hothardware.com/news/qualcomm-snapdragon-8s-gen-3-ai-affordable-premium-phones- Moto X50 Ultra first with 8s Gen 3: https://www.gsmarena.com/motorola_edge_50_pro_to_come_with_snapdragon_8s_gen_3_launch_date_leaks-news-62046.php- Honor Magic6 Ultimate and Magic6 RSR official: https://www.gsmarena.com/honor_announces_porsche_design_magic6_rsr_and_magic6_ultimate_with_unique_looks-news-62049.php- Vivo X Fold3 series coming Mar 26: https://www.gsmarena.com/its_official_the_vivo_x_fold3_series_vivo_pad3_pro_and_vivo_tws_4_buds_are_coming_on_march_26-news-62045.php- Apple + Google Gemini / Open AI rumors: https://www.theverge.com/2024/3/18/24104626/apple-license-google-gemini-generative-ai-openai-chatgpt

Tune into episode 331 of the Mobile Tech Podcast with guests Ephrem Chemaly and Finbarr Moynihan (MediaTek), plus Daniel Bader (Android Police) -- brought to you by MediaTek. This episode comes in two parts. First, we explore MediaTek Dimensity Auto and the company's partnership with NVIDIA. Second (18:53), we review the Nothing Phone (2) and discuss the Honor Magic V2. Finally, we cover news, leaks, and rumors from OnePlus, Samsung, Apple, Google, and MediaTek.Episode Links- Support the podcast on Patreon: https://www.patreon.com/tnkgrl- Donate: https://tnkgrl.com/tnkgrl/- MediaTek: http://www.poweredbymediatek.com/ (sponsor)- MediaTek Dimensity Auto: https://www.mediatek.com/products/automotive- Ephrem Chemaly: https://www.linkedin.com/in/chemaly/- Finbarr Moynihan: https://www.linkedin.com/in/finbarr-moynihan-b653b51/- DanielBader: https://twitter.com/journeydan- My Nothing Phone (2) review: https://hothardware.com/reviews/nothing-phone-2-review- Honor Magic V2: https://www.engadget.com/honors-magic-v2-is-the-thinnest-foldable-phone-to-date-140023005.html- OnePlus 12 renders leak: https://www.gsmarena.com/heres_the_oneplus_12_in_some_leaked_cadbased_renders-news-59188.php- Samsung Galaxy Z series price rumors: https://www.gsmarena.com/leaked_prices_indicate_small_bump_for_galaxy_z_flip5_more_significant_increase_for_z_fold5-news-59176.php- Apple iMac 32" rumors: https://www.gsmarena.com/gurman_apple_is_working_on_a_new_imac_with_an_m3_chip_a_32_imac_planned_for_2024_2025-news-59142.php- Google Tensor rumors: https://www.gsmarena.com/future_google_tensor_chips_might_be_designed_entirely_inhouse_and_not_depend_on_samsung-news-59128.php- MediaTek Dimensity 6100+: https://www.gsmarena.com/mediatek_dimensity_6100_announced_for_future_midrange_smartphones-news-59170.php

In this episode Raquel and Jennifer discuss the book Rage Becomes Her: The Power of Women's Anger by Soraya Chemaly. Chemaly writes, "...our rage is one the most important resources we have, our sharpest tool against both personal and political oppression. Our anger is a vital instrument and a catalyst for change.” Listen in as Raquel and Jennifer talk about rage, how it shows up in their own lives and how it can be utilized constructively. "Be angry. Be loud. Rage becomes you." Indeed!Soraya Chemaly's website: http://www.sorayachemaly.com/10 Simple Words Every Girl Should Learn, http://www.rolereboot.org/culture-and-politics/details/2014-05-10-simple-words-every-girl-learn/index.html“Stop interrupting me.” “I just said that.”“No explanation needed.”Let Raquel and Jennifer know what you think about this and other episodes of Madness Cafe on IG @madnesscafepodcast or by email at madnesscafepodcast@gmail.com.And don't forget to rate and review the show wherever you listen!Thanks for listening and responding!

The outgoing coordinator of the Global Protection Cluster shares some of his impressions of the state of a crucial part of the humanitarian system, the gains made, the challenges that remain, and why it all matters.

Welkom by nog n episode van die podcast! Vandag het Nicola Chemaly in die studio kom kuier! Ons praat oor hoe sy haar skulls prepare vir haar art, Murals wat sy al gedoen het en tattoos!! Dan nog klomp ander lekker goed!! Was n lekker episode!! Hoop julle geniet dit! YouTube

Welkom by nog n episode van die podcast! Vandag het Nicola Chemaly in die studio kom kuier! Ons praat oor hoe sy haar skulls prepare vir haar art, Murals wat sy al gedoen het en tattoos!! Dan nog klomp ander lekker goed!! Was n lekker episode!! Hoop julle geniet dit! YouTube

Was good catching up with my good friend who is doing great things in Singapore with his Mobilus Chinatown community. The Head Coach and former CrossFit Games Athlete shares about his journey growing up, business, opportunity overseas, his CrossFit Games journey, tips on health and fitness and more! Listen in for a chat with a legend of a guy who punches well above his weight and size in all areas of life. #ZealousStateofMind #WesWesNet #GuruofGainz #Mobilus

As with any condition, until we have language for what we are experiencing, until we can name it, we often feel controlled by it. In January of 2019 Soraya Chemaly renamed and redefined anger for us. In a riveting talk based upon her book, “Rage Becomes Her: The Power of Women’s Anger,” Chemaly puts female anger into its societal context, revealing it as a tool of transformation, an untapped resource for change. Soraya Chemaly is the Executive Director of The Representation Project. An award-winning author and activist, she writes and speaks frequently on topics related to gender norms, inclusivity, social justice, free speech, sexualized violence, and technology. In this illuminating talk and Q&A with journalist Carole Carmichael, Chemaly details the very real ways that women are taught from an early age to control and suppress their anger rather than harness it for change—and the way that this socialization is harmful to women and men, and especially to people of color.

GUEST INFO:  SORAYA CHEMALYWays to connect with herTwitter: @schemalyInstagram: @sorayachemalyFacebook: Soraya ChemalyInstagram for Rage Becomes Her: @ragebecomesherSoraya Chemaly’s Website: http://www.sorayachemaly.com/Rage Becomes HerBUY RAGE BECOMES HERWant to check out more of Soraya's Work?Check out all her books hereSoraya's Ted TalkOther events Soraya has spoken atOther online writing that Soraya has doneThe Representation ProjectSign up for their newsletterThe Representation Project's website----SORAYA CHEMALY'S BIOSoraya Chemaly is currently the Executive Director of The Representation Project. An award-winning author and activist, she writes and speaks frequently on topics related to gender norms, inclusivity, social justice, free speech, sexualized violence, and technology. The former director and co-founder of the Women’s Media Center Speech Project, she has long been committed to expanding women’s civic and political participation.Soraya is also the author of Rage Becomes Her: The Power of Women’s Anger, which was recognized as a Best Book of 2018 by the Washington Post, Fast Company, Psychology Today, Autostraddle and NPR and has been translated into several languages. She is a contributor to multiple anthologies, most recently Free Speech in the Digital Age and Believe Me: How Trusting Women Can Change The World. Her work as a writer, activist, and organizer is featured widely in media, books, and academic research.Soraya currently serves on the national boards of the Women's Media Center, Women in Journalism, and the DC Volunteer Lawyers Project. She has also served on the boards of Women, Action and the advisory councils of the Center for Democracy and Technology, VIDA, Secular Woman, FORCE: Upsetting Rape Culture, No Bully, and Common Sense Media DC. As an activist, Ms. Chemaly has spearheaded successful campaigns challenging corporations to address online abuse, restrictive content moderation and censorship, and institutional biases that affect free speech.In 2013, Soraya won the Association for Education in Journalism and Mass Communication’s (AEJMC)'s Award for Feminist Advocacy and the Secular Woman Activism Award. In 2014, she was named one of Elle Magazine's 25 Inspiring Women to Follow in social media, and, in 2016, the recipient of the Women’s Institute for Freedom of the Press’s Women and Media Award. In 2017, she was the co-recipient of the Newhouse Mirror Award for Best Single Feature of 2016 for an in-depth investigative report on free speech and social media, and a Wikipedia Distinguished Service Award for exemplary contributions to the advancement of public knowledge and educational content. In 2019, she was awarded the Feminist Press’ Feminist Power Award. Prior to 2010, Ms. Chemaly spent more than fifteen years as a market development executive and consultant in the media and data technology industries. After several years in market development at the Gannett Corporation, she moved into the data tech sector at Claritas, ending her tenure there as SVP of Marketing Strategy.---------Podcast InfoA new podcast episode drops every Monday.Music credit: L-Ray Music, Courtesy of Shutterstock, Inc.Learn more about your host, Cordelia, by clicking hereBe sure to follow Cordelia on Instagram: @codependentrecoveryWant to help me make this podcast better?  Take an anonymous survey here.---------Workbook + Community + Free ResourcesAre you going through a breakup or divorce?   Here is the link to the 98-page workbook.  Print version + ebook version available worldwide.Want to join the community (i.e., community club or book club)? Click hereWant access to free resources? Click hereNeed help finding a counselor? Click here 

Now one of our guests broke barriers by creating a wonderful underwear line for trans women - a first in the country. This was inspired by her teenage daughter coming out as transgender last year in August. Joanne Chemaly and her daughter Hailie join Sara-Jayne to share their story. See omnystudio.com/listener for privacy information.

There is power in anger. There is purpose in anger. Anger is that beautiful, much-maligned and useful emotion that women, in particular, are discouraged and punished for expressing. SHOW NOTESIn this episode of Crina and Kirsten Get to Work our hosts talk about anger – that much maligned and useful emotion that women, in particular, are discouraged from and punished for expressing.  There is power in anger and there is purpose in anger – even at work.  And it’s time women understood and used their anger in the workplace – for real!  Crina recalls experiences of white-hot anger in her personal life, and little of that in her professional life.  Kirsten admits that she was an early adopter of anger and has honed her expression of it over the years into something that she believes makes her more effective and authentic.Anger at work comes with a strict warning for its use – nothing physical and no yelling!! And if you know you are out of control, we recommend against its use. Now to the juicy topic of anger.Soroya Chemaly is one of the most thoughtful people on the topic of women’s anger.  She believes women are told that anger is an emotion better left unvoiced.  “It is reserved as the moral property of boys and men” says Chemaly.  Chemaly has some other good observations about anger.  Women who are angry are called such things as spoiled, high maintenance, shrill/ugly.  And when we add race and ethnicity to the mix, we get labels like spicy Latina, crazy white women, sad Asian, angry Black woman.  Chemaly notes that instead of getting angry, women tend to cry or be sad or disappointed, use minimizing language and the like.  Chemaly believes these distortions of anger actually negatively affect women’s physical and mental health.  Women are twice as likely as men to have heart problems, anxiety, eating disorders and self-harming behaviors.Women have a lot to be angry about.  According to a New Yorker article, American women between the ages of eighteen and forty-four are nearly twice as likely as men to:Report feeling exhausted every day; Make less money than their male colleagues; of the thirty highest-paying job categories, twenty-six are dominated by men, while women dominate twenty-three of the thirty lowest-paying categories; female patients are treated for pain less often than male patients who present with the same symptoms; one in four women lives with domestic violence; one in five women has been sexually assaulted; and two-thirds of women have experienced street harassment, roughly half of them before they turned seventeen. The Perils and Possibilities of AngerAgainst this backdrop – our hosts dive into anger at work.  Of course, men are generally rewarded for their anger, while women are generally punished.  The issue seems to be that we are comfortable with and assume a purpose in men’s anger, but because we do not feel comfortable with women’s anger, we often impute an intention that is negative – to match our discomfort with the anger.  However, when women explain their anger, it is more likely to advance status in the workplace. (Can Angry Women Get Ahead?).  Explaining and additional information tend to undermine the biases that people form – so explaining your anger substitutes for the negative assumptions people tend to make about women’s anger.Anger can be very useful at work.  People who are able to process their anger and make meaning from it are more creative, more optimistic, create more intimacy and be better problem solvers – and these are all great things for and that we want more of in the workplace. (Can Angry Women Get Ahead?)Our hosts end the episode by examining what smart and thoughtful women have said about anger."I felt like a hand was at my throat when I first started writing. That if I was going to be a proper writer, I’d better be as polite as possible and as calm as possible and as un-angry as possible — and recently I’ve been thinking, you know, fuck that, basically." Zadie Smith"One of the things I wanted was for her [a Netflix tv character she was writing] to be a hothead because it is so unacceptable in society to be an angry Asian woman. You’re supposed to be demure and agreeable. I always had so much impatience and ambition — these things that if you had them, you were supposed to have them secretly." Mindy Kaling"Every woman has a well-stocked arsenal of anger potentially useful against those oppressions, personal and institutional, which brought that anger into being. Focused with precision it can become a powerful source of energy serving progress and change." Audre Lorde"You should be angry. You must not be bitter. Bitterness is like cancer. It eats upon the host. It doesn’t do anything to the object of its displeasure. So use that anger. You write it. You paint it. You dance it. You march it. You vote it. You do everything about it. You talk it. Never stop talking it." Maya Angelou More Good Stuff on AngerCan an Angry Woman Get Ahead?: Status Conferral, Gender, and Expression of Emotion in the Workplace I Used to Insist I Didn’t Get Angry. Not Anymore. (Published 2018)The Perils and Possibilities of AngerSoraya Chemaly: The power of women's anger | TED TalkCan an Angry Woman Get Ahead?: Status Conferral, Gender, and Expression of Emotion in the WorkplaceThe Perils and Possibilities of Anger   

In the countdown to the 2020 election I interviewed Soraya Chemaly, author of Rage Becomes Her: The Power of Women’s Anger - an amazing book she wrote after 2016 election delving into the reasons why women can’t be angry without being called “unhinged” or a “b*”. Our conversation includes: how the progressive white male was most “shocked” with 2016 results why the power differential between men and women hurts EVERYONE (hello, judges of Kamala Harris' facial expressions) why the ideology of separate spheres keeps us divided — and struggling to maintain our mental health, hence all those bubble baths and lavender oil treatments. (Raising my hand to that... its great, right, but... is it really enough?) Soraya also shares the historical context of gender roles and intersectional feminism to provide convincing reasons why self-care rituals fall short of any real solutions while remaining vitally important for us to do. --- About Soraya Soraya Chemaly is currently Executive Director of The Representation Project. An award-winning author and activist, she writes and speaks frequently on topics related to gender norms, inclusivity, social justice, free speech, sexualized violence, and technology. The former director and co-founder of the Women’s Media Center Speech Project, she has long been committed to expanding women’s civic and political participation. Her work as a writer, activist and organizer is featured widely in media, books, and academic research. She is the author of Rage Becomes Her: The Power of Women’s Anger, which has been translated into several languages, and a contributor to multiple anthologies, most recently Free Speech in the Digital Age and Believe Me: How Trusting Women Can Change The World. Prior to 2010, Ms. Chemaly spent more than fifteen years as a market development executive and consultant in the media and data technology industries. After several years in market development at the Gannett Corporation, she moved into the datatech sector at Claritas, ending her tenure there as SVP of Marketing Strategy. Soraya currently serves on the national boards of the Women's Media Center, Women in Journalism, and the DC Volunteer Lawyers Project. She has also served on the boards of Women, Action and the advisory councils of the Center for Democracy and Technology, VIDA, Secular Woman, FORCE: Upsetting Rape Culture, No Bully, and Common Sense Media. As an activist, Ms. Chemaly has spear-headed multiple successful campaigns challenging corporations to address online harassment and abuse, restrictive content moderation and censorship, and institutional biases that affect free speech. In 2013, Soraya won the Association for Education in Journalism and Mass Communication’s (AEJMC)'s Award for Feminist Advocacy and the Secular Woman Activism Award. In 2014, she was named one of Elle Magazine's 25 Inspiring Women to Follow in social media, and, in 2016, the recipient of the Women’s Institute for Freedom of the Press’s Women and Media Award. In 2017, she was the co-recipient of the Newhouse Mirror Award for Best Single Feature of 2016 for an in-depth investigative report on free speech and social media, and a Wikipedia Distinguished Service Award for exemplary contributions to the advancement of public knowledge and educational content. In 2019, she was awarded the Feminist Press’ Feminist Power Award. Website | Instagram | Twitter | Facebook | Books --- Get the Body Kindness book It's available wherever books and audiobooks are sold. Read reviews on Amazon and pick up your copy today! Order signed copies and bulk discounts here! --- Donate to support the show Thanks to our generous supporters! We're working toward our goal to fund the full season. Can you donate? Please visit our Go Fund Me page. --- Get started with Body Kindness Sign up to get started for free and stay up to date on the latest offerings --- Become a client Check out BodyKindnessBook.com/breakthrough for the latest groups and individual support sessions --- Subscribe to the podcastWe're on iTunes, Stitcher, Spotify and iHeartRadio. Enjoy the show? Please rate it on iTunes! Have a show idea or guest recommendation? E-mail podcast@bodykindnessbook.com to get in touch. --- Join the Facebook groupContinue the episode conversations with the hosts, guests, and fellow listeners on the Body Kindness Facebook group. See you there! Nothing in this podcast is meant to provide medical diagnosis, treatment, cure, or prevent any disease or condition. Individuals should consult a qualified healthcare provider for medical advice and answers to personal health questions.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Go online to PeerView.com/ZXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients, Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting, Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients.

Giorgio Chemaly is an entrepreneur and coach based out of Beirut, Lebanon. After connecting with Trey on Linkedin recently, we invited Giorgio to come on the podcast and talk about his entrepreneurship journey, quarantine life in Lebanon and The Power of LinkedIn to connect us with new friends and colleagues across the map. Connect with Giorgio on LinkedIn! www.upgrey.com Connect with GRAVITY: www.gravitymemphis.com @gravitymemphis on IG Join the GRAVITY Network Group on LinkedIn! Interested in the software discussed on the show? Message us on LinkedIn or Instagram for more info!

In this episode, we discuss the disparate gender experiences of anger and the impacts it has on individuals, relationships, and society. Soraya Chemaly is an award-winning writer and media critic whose writing appears regularly in national and international media. She speaks frequently on topics related to inclusivity, freedom of speech, gender roles in human systems, data, and technology. Ms. Chemaly is co-founder and director of the Women's Media Center Speech Project and spear-headed multiple successful campaigns challenging corporations to address inclusivity, online harassment and hate, and algorithmic bias. In 2017, she was a recipient of the Newhouse Mirror Award for Best Single Feature of 2016 for an in-depth investigative report, The Secrets of The Internet, about social media companies and their regulation of online hate, harassment, and freedom of expression. Her recent book, Rage Becomes Her: The Power of Women's Anger, was named one Best Book of 2018 by The Washington Post, Fast Company, Psychology Today and Book Riot. In this episode, we discuss: ·      Gendered assumptions when it comes to the emotions we feel, especially anger. ·      The difference of how genders are taught to process and express anger. ·      Misconceptions about testosterone and the relationship between testosterone and aggression. ·      The impacts of detaching anger from femininity. ·      How anger is perceived differently by race. ·      How vulnerability and fragility is programmed into women from a young age and the impact that has. ·      The unhealthy ways in which unprocessed anger is presenting in our lives. ·      The complicated dynamics – within society and relationships – surrounding caretaking responsibilities. ·      And what we can do to begin to address unprocessed anger. You can find and follow Soraya here: Website Instagram @sorayachemaly Facebook /sorayachemaly Twitter @schemaly Her book – Rage Becomes Her: The Power of Women's Anger SHOP!! Shop effective plant-based hand soap, cleaners, shampoo, conditioner, and more at PURACY. Use Code PURE15 for 15% off. Check out additional DISCOUNTS in my SHOP! GIVEAWAY!! We are giving away six sex toys from CalExotics, the first woman-owned sex toy company EVER. Susan Colvin, the owner, launched the business 25 years ago and is a pioneer in the space — she's launched over a million pleasure products over the years! Her mission is to bring pleasure to ALL people no matter their gender, race, socioeconomic background, or preferences.  Laguna Beach Lover "Marvelous Tickler"- a new release from CalExotics' Mini Marvels Shameless "Seducer" French Kiss Charmer Glam Rechargeable Butterfly Kiss  Listen to Ep. 34: Live Your Best Sex Life with Isharna Walsh to learn more. www.CalExotics.com.  RUNS THROUGH MARCH 31! Please SUBSCRIBE, SHARE, RATE, and REVIEW the podcast! Follow the podcast on Instagram @TheBetterYouPodcast or Facebook @TheBetterYouPodcast. And you can email the podcast at TheBetterYouPodcast@gmail.com Follow me on all the socials: Instagram @kaciemain_writes, Facebook @kaciemain.write, or Twitter @kaciemain_write. Find my book – I Gave Up Men for Lent, the story of a jaded, hopelessly romantic, health-conscious party girl's search for meaning – on Amazon, Kindle, and Audible. And for everything else you want to know about me, visit my website at www.kaciemain.com     Some links are Amazon Affiliate links.

Feminists get a bad rap for being angry. But what would it be like if women were allowed to embrace their anger? American writer Soraya Chemaly has been calling for this shift for years. A prolific voice on the role of gender in culture and politics,  she has had a long career in media and technology. And, she has encountered a lot to be angry about. Her latest book, Rage Becomes Her is a celebration of female anger. It tackles the highly gendered way our culture regards anger, and questions why angry men are strong but angry women are crazy. This episode is part of a six-part ‘It’s A Long Story’ series featuring alumni from our All About Women festival. All About Women returns to Sydney Opera House on 8 March 2020.

Soraya Chemaly - award-winning writer and media critic, director of the Women's Media Center Speech Project and author of the best-selling book Rage Becomes Her - joins me in a pointed conversation about the complicated relationship between society, women and anger. From her personal lightbulb moment to how we socialize young girls to "be nice," Soraya explains the suffocating burden placed on women today and what it really means to be emotionally free. We also discuss the added weight carried by those with intersectional identities and how they impact our ability to succeed. Listen and learn, friends. Soraya is a real one. 

Kelly interviews feminist writer Soraya Chemaly, author of Rage Becomes Her: The Power of Women's Anger. They discuss the role of anger in the 2016 and 2020 presidential races, modeling emotional competence for children, and Soraya's work as Director of the Women's Media Center Speech Project.

Kelly interviews feminist writer Soraya Chemaly, author of Rage Becomes Her: The Power of Women's Anger. They discuss the role of anger in the 2016 and 2020 presidential races, modeling emotional competence for children, and Soraya's work as Director of the Women's Media Center Speech Project.

Anger, one of the darker emotions that women have historically learned to suppress & transfer into other more acceptable emotions like anxiety, sadness, and depression, is actually a valid and valuable tool for creating change in our personal lives and in the world. This is not the first time in history women’s anger has been at the front line of activism. Women’s anger has always fueled change. As “the first line of defense against injustice,” (Chemaly) when women get fed up, the world changes. This episode is one of a three-part series on Women’s Emotional Freedom & Transformation. Join Amaya and Leigh as they discuss Soraya Chemaly’s book, Rage Becomes Her, a book about the power of women’s anger. In this episode, we seek answers to questions like--why do we favor certain emotions over others, and how is this limiting us? What are the causes of women's anger, and can we give ourselves (and others) permission to be angry about injustices in our personal lives and in the world? Can we honor our emotions and create the emotional freedom that will open to deeper personal and collective growth? We believe we can and must. So, if you are constantly policing your anger, shaming yourself, or suppressing and redirecting your anger into sadness, anxiety, and depression, you may like what we have to say, and you’ll definitely want to read this book. Cover art entitled, “They Called Her Rage,” by Alabama artist June Reddix-Stennis @flygirljune. This piece was a part of a series of murals entitled, "And Then She," which June created for a public space in downtown Mobile, Alabama in response to the first Women's March in 2017. June says her decision to create this work came about "the same time when the United States was exploding with chaos and hate. I couldn't focus. All I could think about was the black dead bodies killed by police that kept popping in my timeline on social media. I felt like screaming and weeping. All my former female colleagues were out all across the nation preparing for the march. I was at home with a sheet of plywood, buckets of latex and acrylic paint on a tarp set up in my home office." To see more of her paintings visit her FB page @flygirljune. Listen and rate us on iTunes, Spotify, SoundCloud, & GooglePlay Follow us on FB & Instagram @FemmSouth Stay up to date with our newsletter by visiting www.FemmSouth.com

Women are taught from birth to repress their rage. But what would happen if women learnt to embrace anger, and unleash it upon the world? At All About Women 2019 writer and activist Soraya Chemaly called for an ungendering of emotion for the benefit of everybody. In this rousing session hosted by Fauziah Ibrahim she discusses ways women can joyfully express and find power in their rage.

In this full episode of "Exploring Minds", Michele Carroll and Soraya Chemaly explore the main concepts in Soraya's book Rage Becomes Her, including intersectionality, the effects of internalized anger and the gender wage gap. - Soraya Chemaly is an award-winning writer and media critic whose writing appears regularly in national and international media including The Atlantic, The Nation, Verge, Quartz, TIME, Salon, The Guardian and The New Statesman. She speaks frequently on topics related to inclusivity, free speech, sexualized violence, data and technology. She is the director of the Women’s Media Center Speech Project an initiative dedicated to expanding women’s civic and political participation. She currently serves on the national boards of the Women's Media Center and Women, Action and the Media, as well as on the advisory councils of the Center for Democracy and Technology, VIDA, and Common Sense Media. As an activist, Ms. Chemaly has spear-headed multiple successful campaigns challenging corporations to address online harassment and abuse, restrictive content moderation and censorship, and institutional biases that affect free speech. Prior to 2010, Ms. Chemaly spent more than fifteen years as a market development executive and consultant in the media and data technology industries. In the early 1990s, after several years at the Gannett Corporation, where she was involved in establishing the newspaper industry’s first subscriber and advertisers databases, she moved into the datatech sector with Claritas Inc. These work experiences give her unique insights into internet data development, leading her to fight vigorously again their abuses. In 2013, Soraya won the Association for Education in Journalism and Mass Communication’s (AEJMC)'s Donna Allen Award for Feminist Advocacy and the Secular Woman Feminist Activism Award. In 2014, she was named one of Elle Magazine's 25 Inspiring Women to Follow in social media. In 2016, Soraya was the recipient of the Women’s Institute for Freedom of the Press’s Women and Media Award. In 2017, she was the co-recipient of the Newhouse Mirror Award for Best Single Feature of 2016 for an in-depth investigative report on free speech and online content moderation, The Secrets of The Internet, and a Wikipedia Distinguished Service Award, for exemplary contributions to the advancement of public knowledge and the collection, development, and dissemination of educational content. She is the author of the book, Rage Becomes Her: The Power of Women’s Anger. In 2013, she won the Association for Education in Journalism and Mass Communication’s (AEJMC)'s Donna Allen Award for Feminist Advocacy and the Secular Woman Feminist Activism Award. In 2014, she was named one of Elle Magazine's 25 Inspiring Women to Follow on Twitter. She writes and speaks regularly about gender, media, tech, education, women's rights, sexual violence and free speech. - SUPPORT US ON PATREON: https://www.patreon.com/exploringmindsshow FOLLOW ALONG FOR UPDATES AND NEW EPISODES: Discord - https://discord.gg/YhaAcN3 Facebook - https://www.facebook.com/exploringmindsshow Twitter - https://twitter.com/ExploreMinds_TV Instagram - https://www.instagram.com/exploreminds_tv/ Website - exploringminds.show — Exploring Minds with Michele Carroll is the online show committed to exploring the world beyond talking points. Thank you for listening! Support the show.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Go online to PeerView.com/JVG860 to view the entire program with slides. Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV. Upon completion of this activity, participants should be better able to: Identify unmet needs associated with the management of CMV infection in HCT recipients, Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting, Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT.

Bottling up anger has been linked to a degrade in overall health, especially in autoimmune diseases where 75% of American patients are female. We discuss this and other ways women are psychologically and physically suppressed in society with Soraya Chemaly, author of the bestselling book ”Rage Becomes Her.”

Rage Becomes Her author Sorya Chemaly & Chicano Writer Christine Granados by Tony Diaz Tells It Like It Is

Anger is a powerful emotion -- it warns us of threat, insult, indignity and harm. But across the world, girls and women are taught that their anger is better left unvoiced, says author Soraya Chemaly. Why is that, and what might we lose in this silence? In a provocative, thoughtful talk, Chemaly explores the dangerous lie that anger isn't feminine, showing how women's rage is justified, healthy and a potential catalyst for change. Hosted on Acast. See acast.com/privacy for more information.

Wut ist eine mächtige Emotion -- sie warnt uns vor Gefahren, Beleidigungen, Demütigungen und Leid. Auf der ganzen Welt wird Frauen und Mädchen aber beigebracht, ihre Wut besser zu unterdrücken, sagt Autorin Soraya Chemaly. Warum ist das so und was verlieren wir mit diesem Schweigen? In einem provokanten, nachdenklichen Vortrag geht Chemaly der gefährlichen Lüge nach, dass Wut nicht feminin sein soll und zeigt wie die Wut der Frauen gerechtfertigt, gesund und ein potentieller Katalysator für Veränderung ist.

La colère est une émotion puissante. Elle nous prévient des menaces, des insultes, des atteintes à la dignité et des préjudices. Toutefois, partout dans le monde, on inculque aux filles et aux femmes qu'il est préférable de réduire la colère au silence, nous dit Soraya Chemaly. Pourquoi ? Que risquons-nous de perdre dans ce silence ? Dans une intervention aussi réfléchie que provocante, Chemaly explore les mensonges dangereux qui veulent nous faire croire que la colère n'est pas une émotion féminine. La colère des femmes est non seulement légitime, affirme-t-elle, mais elle est saine et est un catalyseur potentiel du changement.

La ira es una emoción poderosa. Nos advierte de la amenaza, el insulto, la vergüenza y el daño. Sin embargo, a las niñas y mujeres de todo el mundo se les enseña que la ira es mejor silenciarla, dice la escritora Soraya Chemaly. ¿Por qué pasa eso y qué podríamos perder en ese silencio? En una charla reflexiva y provocadora, Chemaly examina la peligrosa mentira de que la ira no es femenina, mostrándonos cómo la ira de las mujeres es justificada, saludable y un posible catalizador del cambio.

A raiva é uma emoção poderosa - ela nos previne de ameaça, insulto, indignação e injustiça. Mas em todo o mundo, meninas e mulheres são ensinadas que é melhor silenciar a raiva delas, diz a autora Soraya Chemaly. Por que isso acontece e o que podemos perder com esse silêncio? Em uma palestra provocativa e reflexiva, Chemaly explora a mentira perigosa de que a raiva não é feminina, mostrando como a raiva das mulheres é justificada, saudável e um potencial catalisador de mudança.

Anger is a powerful emotion -- it warns us of threat, insult, indignity and harm. But across the world, girls and women are taught that their anger is better left unvoiced, says author Soraya Chemaly. Why is that, and what might we lose in this silence? In a provocative, thoughtful talk, Chemaly explores the dangerous lie that anger isn't feminine, showing how women's rage is justified, healthy and a potential catalyst for change.

"Our anger has all this information, it has all this expertise, it has all this experience and we should respect it in ourselves and in other women." - Soraya Chemaly     This episode is brought to you in collaboration with Fast Mary's.     Today's featured interview is with Soraya Chemaly. She is the author of Rage Becomes Her: The Power of Women’s Anger, named a Best Book of 2018 by NPR, Washington Post and others, including some of our favorites Autostraddle, Psychology Today, and Bitch magazine. This book is about the ways that the social construction of emotion, anger in particular, affect women’s personal, professional and political equality. Chemaly is a prolific writer whose work focuses on the role of gender and identity in culture, education and technology. She is also the director of the Women’s Media Center Speech Project, an initiative devoted to expanding women’s civic and political participation.     Connect with Soraya and learn more about her work on Twitter, Instagram, Facebook, and LinkedIn.     Soraya's book recommendations: Eloquent Rage: A Black Feminist Discovers Her Superpower by Brittney Cooper Good and Mad: The Revolutionary Power of Women's Anger by Rebecca Traister The Power by Naomi Alderman     In this episode, I also chat with Kristen and Kerry, two of the organizers of 24in48, a 48 hour readathon happening January 26-27. Participants will have an opportunity to win a three month subscription Feminist Book Club box so sign up here if you're feeling lucky: https://24in48.com/ Or if you prefer a little more control in your life, use code PODCAST to get a discount on your February box at feministbookclub.com/subscribe. Connect with the #24in48 community on Instagram, Facebook, Twitter.       About today's sponsor: Fast Mary’s Bloody Mary Enhancer is a naturally vegan, gluten-free, Bloody Mary seasoning concentrate.  Handcrafted and infused to perfection, Fast Mary's turns any ordinary Bloody Mary into the ultimate culinary concoction. Learn more at fastmarys.com     Website: feministbookclub.com Instagram: @feministbookclubbox Facebook: Feminist Book Club Twitter: @fmnstbookclub Email newsletter: http://eepurl.com/dvRgvD   - Logo and web design by Shatterboxx  Original music by @amiofficialmusic Transcript for this episode: bit.ly/FBCtranscript3   Get $5 off your Feminist Book Club Box with the code PODCAST at feministbookclub.com/subscribe.  

Show #219 | Guest: Soraya Chemaly | Show Summary: Show #219 | October 20, 2018 | Women get told to smile - a lot. Research shows that a neutral expression is perceived on a man's face as neutral, but as angry or negative on a woman. And all kinds of ugly words are reserved for woman who show anger. Where others see female anger as something to fear or reject, Soraya Chemaly sees strength, even opportunity. With the Women's Media Center Speech Project, and as organizer of the Safety and Free Speech Coalition, she's pushed for wider exposure of women's voices, and worked to curb online abuse. Now, she's encouraging women to embrace their rightful anger. In her new book Rage Becomes Her, Chemaly links patriarchy and misogyny to the traditional repression of women's full range of emotion. She goes beyond simple rejection of "Smile, honey!" to an embrace of anger as a personally and politically transformative tool. Soraya Chemaly joins Angie Coiro in a provocative conversation about a downright dangerous idea.

The Social Network Show welcomes Soraya Chemaly to the May 6, 2014 episode. Ms. Chemaly, a feminist writer, media critic and activist shares with us the story of the very interesting development of the campaign on Facebook to get the management to recognize that misogynistic content is hate speech. If you are worried about human rights on social media, listen to this show and hear how this campaign got started. Hear how Facebook reacted and what they are doing now. Soraya Chemaly is a feminist writer, media critic and activist whose work focuses on women's rights and the role of gender in politics, religion and popular culture. Her work appears regularly in Salon, The Huffington Post, RHRealityCheck, Fem2.0, Role Reboot and the Feminist Wire. She also writes for The Guardian, Ms. Magazine and CNN. Ms. Chemaly is a frequent radio, television and online commentator and was, recently, one of the primary organizers of a successful social media campaign demanding that Facebook recognize misogynistic content as hate speech. She speaks regularly on the topic of gender, violence and free speech. Ms. Chemaly was the recipient of the 2013 Secular Woman Activist of the Year Award, as well as this year's Donna Allen Award for Feminist Advocacy. Ms. Chemaly returned to feminist activism and writing after a professional career in strategic planning, marketing and business development in the media, data and technology fields. .